Akiko Uenaka

Immunology and Microbiology · Life Sciences

26h-index2.2kcitations106works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(73), T-cell and B-cell Immunology(28), Immune Cell Function and Interaction(27), Cancer Immunotherapy and Biomarkers(22), Monoclonal and Polyclonal Antibodies Research(17)

Publications106 total

Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically<i>S-</i>Cationized Full-Length and Water-Soluble Denatured Proteins
Bioconjugate Chemistry·2015· 13 cited
Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient
PLoS ONE·2015· 6 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Eiichi Nakayama(44), Midori Isobe(12), Yuji Noguchi(11), Hiroshi Shiku(11), Toshiro Ono(10), Hisashi Wada(10), Lloyd J. Old(10), Shuichiro Sato(9), Mikio Oka(8), Morito Monden(7), Roger Murphy(6), Shingo Eikawa(6), Yoshihiro Ohue(6), Takashi Saika(5), Eiichi Sato(5), Yuichiro� Doki(5), Gerd Ritter(5), Eric W. Hoffman(5), Kazuhiko Nakagawa(5), Heiichiro Udono(4)